Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Steve Smith, a…
Drug developers must undergo a stringent set of testing and regulatory steps in the journey towards drug approval. In the European Union (EU), the Committee for Medicinal Products for Human…
According to a story from Scleroderma News, findings from the recent Phase 2 EDITA clinical trial suggested that ambrisentan (marketed as Letairis), which is approved to treat pulmonary arterial hypertension…
Pulmonary arterial hypertension (PAH), a rare and chronic disorder characterized by high blood pressure (hypertension) in the lungs that causes the pulmonary arteries to thicken or harden, most often manifests…
Pulmonary arterial hypertension (PAH) is a rare, chronic, and progressive disorder characterized by high blood pressure in the lungs. This causes pulmonary arteries to thicken or harden, which eventually puts…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
According to a story from Healio, the investigational therapy sotatercept has been given Priority Review status from the US Food and Drug Administration (FDA). The therapy is in development as…
Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…
When it comes to finding novel ways to treat or cure cardiovascular diseases, Cereno Scientific is committed to making change. The clinical-stage biotechnology company works in the realm of both…
From May 13-18, 2022, the American Thoracic Society (ATS) held its Annual Meeting, where researchers and stakeholders discussed research, patient care, and public health trends within the fields of…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Pulmonary arterial hypertension (PAH) is a chronic and progressive form of high blood pressure in the lungs which can result from a number of causes: HIV, sickle cell disease,…
This year, the National Lipid Association held its Scientific Sessions from June 2-5, 2022. During the Scientific Sessions, attendees discussed new research, clinical best practices, and other topics within this…
Dr. Omar P. Haqqani, MD FACS is currently the Chief of Vascular and Endovascular Surgery at the Vascular Health Clinics. He has a keen interest in understanding and addressing vascular…
Korea began its use of effective therapies for idiopathic pulmonary arterial hypertension (IPAH) early in 2000. Idiopathic hypertension has no apparent cause. Yet there have been very few studies assessing…
According to a recent press release, the Australian Human Research Ethics Committee (HREC) has granted approval to Claritas Pharmaceuticals' submission for R-107. Now, the company is free to move forward with…
According to a recent press release from Respira Therapeutics, their investigational treatment for pulmonary arterial hypertension (PAH), RT234, has just been administered to the first patient in a phase 2b…
Diagnosing a rare disease early is important, as it allows for prompt intervention and treatment. Recently, researchers took large steps forward in the diagnostics of pulmonary arterial hypertension (PAH) in…
The Pulmonary Hypertension Association recently announced it is offering junior investigators who are interested in pulmonary arterial hypertension (PAH) a two-year grant. Pulmonary Arterial Hypertension (PAH) Pulmonary arterial hypertension (PAH)…
Life with a rare disease can be difficult and scary, especially when you can't be sure what the future holds. Jessica Calkins, a 37-year-old mother from Washington, understands this experience…
The University of Pittsburgh School of Medicine along with Prairie View A&M University, have recently uncovered that there are some cancer drugs which could be used as an effective treatment…
In the past, imatinib has shown promise for treating patients with pulmonary arterial hypertension (PAH). But specialty pharmaceutical company Tenax Therapeutics, Inc. ("Tenax") believed that it could create a specialty,…
A rare disease diagnosis can change your life; Mari Jackson knows this firsthand. She received a surprise diagnosis of pulmonary arterial hypertension (PAH) at age 48. Her symptoms began suddenly,…
According to a story from news.cision.com, the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CS1, an investigational drug being developed by the…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
